(Q35050581)

6 August 2017

1 reference

title

Nitric oxide-releasing drugs (English)

1 reference

6 August 2017

2

Louis J Ignarro

1 reference

6 August 2017

1

Claudio Napoli

1 reference

6 August 2017

publication date

10 January 2002

1 reference

Annual Review of Pharmacology and Toxicology

6 August 2017

published in

1 reference

6 August 2017

volume

43

1 reference

6 August 2017

page(s)

97-123

1 reference

N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin

6 August 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

The role of nitric oxide in tissue destruction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

The effect of aspirin and two nitric oxide donors on the infarcted heart in situ

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide in the vasculature: physiology and pathophysiology

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

The oxidation hypothesis of atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide donors increase mucus gel thickness in rat stomach.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide: not just a negative inotrope

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide as a signaling molecule in the vascular system: an overview.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide and atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Local drug delivery: an emerging approach in the treatment of restenosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Role of nitrates in acute myocardial infarction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Vasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaque

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Involvement of nitric oxide in the ocular hypotensive action of nipradilol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide and its role in apoptosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Pranidipine enhances the action of nitric oxide released from endothelial cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Mildly Oxidized Low-Density Lipoprotein Impairs Responses of Carotid but Not Basilar Artery in Rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Oxidation-sensitive transcription factors and molecular mechanisms in the arterial wall.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Vitamin E and heart disease: basic science to clinical intervention trials

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Selective COX-2 inhibitors: are they safe for the stomach?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Inhaled nitric oxide in cardiology

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

NO-aspirin protects from T cell–mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Bradykinin metabolism in the isolated perfused rabbit heart

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide-releasing polymers containing the [N(O)NO]- group

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Aspirin: new cardiovascular uses for an old drug

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Depletion of intracellular glutathione reduces mutations by nitric oxide-donating drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Urinary NItrotyrosine Content as a Marker of Peroxynitrite-induced Tolerance to Organic NItrates

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Gastric toxicity of antiplatelet therapy with low-dose aspirin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Interactions among ACE, kinins and NO.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Guanylate cyclase activation by nitroprusside and nitrosoguanidine is related to formation of S-nitrosothiol intermediates

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Coronary stenosis dilatation induced by L-arginine

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Overall cardiovascular profile of sildenafil citrate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Atherogenesis and the arginine hypothesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite possible involvement of S-nitrosothiols

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nebivolol Induces Endothelium Dependent Relaxatíons of Canine Coronary Arteries

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitroprusside-related cyanide poisoning. Time (long past due) for urgent, effective interventions

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effects of changing the availability of the substrate for nitric oxide synthase by L-arginine administration on coronary vasomotor tone in angina patients with angiographically narrowed and in patients with normal coronary arteries

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide: a physiologic messenger

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Oral L-arginine in patients with coronary artery disease on medical management

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

NO-aspirins: a class of new anti-inflammatory and antithrombotic agents.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Sodium nitroprusside: twenty years and counting

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide mediated venodilator effects of nebivolol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single dose in rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Endothelial dysfunction: from physiology to therapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effect of L-arginine administration on myocardial thallium-201 perfusion during exercise in patients with angina pectoris and normal coronary angiograms

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Long-term treatment with nipradilol, a nitric oxide-releasing beta-adrenergic blocker, enhances postischemic recovery and limits infarct size

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Biocompatibility aspects of new stent technology

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Plasma alpha-tocopherol and coronary endothelium-dependent vasodilator function

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.43.100901.140226

Identifiers

DOI

10.1146/ANNUREV.PHARMTOX.43.100901.140226

1 reference

6 August 2017

1 reference